Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference22 articles.
1. Tamoxifen for early breast cancer: an overview of the randomised trials
2. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
3. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women
4. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
5. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Chemoprevention—Historical Perspectives and Current Trends;Current Breast Cancer Reports;2024-01-03
2. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ;JAMA Surgery;2023-12-01
3. Non-systemic Approaches for Ductal Carcinoma In Situ: Exploring the Potential of Ultra-flexible Combisomes as a Novel Drug Delivery Strategy—a Review;AAPS PharmSciTech;2023-05-12
4. Risk management recommendations and patient acceptance vary with high-risk breast lesions;The American Journal of Surgery;2022-01
5. Endocrine prevention of breast cancer;Molecular and Cellular Endocrinology;2021-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3